Federico Caobelli1, Martin Braun2, Philip Haaf3, Damian Wild2, Michael J Zellweger3. 1. Nuclear Medicine Department, University Hospital Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland. Federico.caobelli@usb.ch. 2. Nuclear Medicine Department, University Hospital Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland. 3. Cardiology Department, University Hospital Basel, University of Basel, Basel, Switzerland.
Abstract
PURPOSE: While a visual interpretation of 99mTc-DPD scintigraphy by means of Perugini score can provide a reliable diagnosis of transthyretin-related (ATTR) cardiac amyloidosis (CA), a quantitative approach is expected to play a major role in risk stratification and therapy evaluation. The aim of our study was to test the feasibility of a quantitative assessment and to correlate various parameters to Perugini score. METHODS: in this retrospective study, consecutive patients underwent a 99mTc-DPD whole-body bone scintigraphy and a SPECT/CT of the thorax. XSPECT-QUANT software was used to quantify the DPD uptake in the heart. RESULTS: Thirteen patients were included. CA was confirmed in 8 and rejected in 5. Myocardial SUVmax and SUVpeak showed a fairly strong correlation with Perugini score (both ρ = .71, P = .006). Same held true for to-bone normalized values (both ρ = .75, P = .003). There was a great degree of overlap for quantitative values in patients with Perugini score 2 and 3. CONCLUSION: Quantitative 99mTc-DPD SPECT/CT in suspected ATTR CA patients is feasible and allows for a more accurate assessment of myocardial uptake.
PURPOSE: While a visual interpretation of 99mTc-DPD scintigraphy by means of Perugini score can provide a reliable diagnosis of transthyretin-related (ATTR) cardiac amyloidosis (CA), a quantitative approach is expected to play a major role in risk stratification and therapy evaluation. The aim of our study was to test the feasibility of a quantitative assessment and to correlate various parameters to Perugini score. METHODS: in this retrospective study, consecutive patients underwent a 99mTc-DPD whole-body bone scintigraphy and a SPECT/CT of the thorax. XSPECT-QUANT software was used to quantify the DPD uptake in the heart. RESULTS: Thirteen patients were included. CA was confirmed in 8 and rejected in 5. Myocardial SUVmax and SUVpeak showed a fairly strong correlation with Perugini score (both ρ = .71, P = .006). Same held true for to-bone normalized values (both ρ = .75, P = .003). There was a great degree of overlap for quantitative values in patients with Perugini score 2 and 3. CONCLUSION: Quantitative 99mTc-DPD SPECT/CT in suspected ATTR CA patients is feasible and allows for a more accurate assessment of myocardial uptake.
Entities:
Keywords:
99mTc-DPD SPECT/CT; ATTR cardiac amyloidosis; Bone scan; Metabolic disease
Authors: Maria Papathanasiou; Christoph Rischpler; Lukas Kessler; Pedro Fragoso Costa; David Kersting; Walter Jentzen; Manuel Weber; Peter Lüdike; Alexander Carpinteiro; Sara Oubari; Tim Hagenacker; Andreas Thimm; Tienush Rassaf; Ken Herrmann Journal: J Nucl Cardiol Date: 2022-05-13 Impact factor: 5.952
Authors: Brett W Sperry; Timothy M Bateman; Esma A Akin; Paco E Bravo; Wengen Chen; Vasken Dilsizian; Fabien Hyafil; Yiu Ming Khor; Robert J H Miller; Riemer H J A Slart; Piotr Slomka; Hein Verberne; Edward J Miller; Chi Liu Journal: J Nucl Cardiol Date: 2022-07-21 Impact factor: 3.872
Authors: Golnaz Roshankar; Geneva C White; Sebastien Cadet; Nowell M Fine; Denise Chan; James A White; Victor Jimenez-Zepeda; Piotr J Slomka; Robert J H Miller Journal: J Nucl Cardiol Date: 2021-10-03 Impact factor: 3.872
Authors: Weijia Li; Dipan Uppal; Yu-Chiang Wang; Xiaobo Xu; Damianos G Kokkinidis; Mark I Travin; James M Tauras Journal: Diagnostics (Basel) Date: 2021-05-30
Authors: Sharmila Dorbala; Mi-Ae Park; Sarah Cuddy; Vasvi Singh; Kyle Sullivan; Sirwoo Kim; Rodney H Falk; Viviany R Taqueti; Hicham Skali; Ron Blankstein; Camden Bay; Marie F Kijewski; Marcelo F Di Carli Journal: J Nucl Med Date: 2020-09-04 Impact factor: 11.082